Abstract
Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Letters in Drug Design & Discovery
Title: Specificity of Three Vasopressin Receptor Antagonists
Volume: 8 Issue: 6
Author(s): Jeremy T. Saks, Barbara Truitt and Menachem Shoham
Affiliation:
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Abstract: Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Export Options
About this article
Cite this article as:
T. Saks Jeremy, Truitt Barbara and Shoham Menachem, Specificity of Three Vasopressin Receptor Antagonists, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906794
DOI https://dx.doi.org/10.2174/157018011795906794 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Role of Apoptosis in the Pathogenesis of Contrast Media-induced Nephropathy and Hints for its Possible Prevention by Drug Treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular and Molecular Mechanisms of Curcumin in Thyroid Gland Disorders
Current Medicinal Chemistry Combination of Functional Cardiomyocytes Derived from Human Stem Cells and a Highly-Efficient Microelectrode Array System: An Ideal Hybrid Model Assay for Drug Development
Current Stem Cell Research & Therapy Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Meet Our Editor
Current Clinical Pharmacology NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Nanocapsulated Ascorbic Acid in Combating Cerebral Ischemia Reperfusion- Induced Oxidative Injury in Rat Brain
Current Alzheimer Research Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Colchicine in Neurosurgery
Current Pharmaceutical Design Editorial (Thematic Issue: Perspectives of Antiarrhythmic Therapy: New Trails, Challenges and Pitfalls)
Current Pharmaceutical Design HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) Anticancer Activities and Mechanisms of Bisdioxopiperazine Compounds Probimane and MST-16
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Current Chemical Biology